<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Complications of nephrotic syndrome in children</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Complications of nephrotic syndrome in children</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Complications of nephrotic syndrome in children</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Patrick Niaudet, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Tej K Mattoo, MD, DCH, FRCP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alison G Hoppin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 10, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The nephrotic syndrome is caused by renal diseases that increase the permeability across the glomerular filtration barrier. It is classically characterized by four features, but the first two are used diagnostically because the last two may not be seen in all patients:</p><p class="bulletIndent1"><span class="glyph">●</span>Nephrotic range proteinuria – Urinary protein excretion greater than 50 mg/kg per day</p><p class="bulletIndent1"><span class="glyph">●</span>Hypoalbuminemia – Serum albumin concentration less than 3 g/dL (30 g/L)</p><p class="bulletIndent1"><span class="glyph">●</span>Edema</p><p class="bulletIndent1"><span class="glyph">●</span>Hyperlipidemia</p><p></p><p>Complications in children result from abnormalities directly related to the nephrotic syndrome and secondarily from therapy used for its treatment.</p><p>The five major complications directly related to the underlying nephrotic syndrome in children will be reviewed here:</p><p class="bulletIndent1"><span class="glyph">●</span>Infection</p><p class="bulletIndent1"><span class="glyph">●</span>Thromboembolism</p><p class="bulletIndent1"><span class="glyph">●</span>Renal insufficiency</p><p class="bulletIndent1"><span class="glyph">●</span>Anasarca</p><p class="bulletIndent1"><span class="glyph">●</span>Hypovolemia</p><p></p><p>The clinical manifestations, diagnosis, etiology, and treatment, including complications due to therapy in children with nephrotic syndrome, are discussed separately. (See  <a class="medical medical_review" href="/d/html/6101.html" rel="external">"Clinical manifestations, diagnosis, and evaluation of nephrotic syndrome in children"</a> and  <a class="medical medical_review" href="/d/html/6130.html" rel="external">"Treatment of idiopathic nephrotic syndrome in children"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">INFECTION</span><span class="headingEndMark"> — </span>Children with nephrotic syndrome are at increased risk of infection. The following factors may contribute to this problem:</p><p class="bulletIndent1"><span class="glyph">●</span>Reduced serum concentrations of immunoglobulin G (IgG) [<a href="#rid1">1</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Impaired ability to make specific antibodies [<a href="#rid2">2</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Decreased levels of the alternative complement pathway factors B and D [<a href="#rid3">3-5</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Immunosuppressive therapy</p><p></p><p>The frequency and types of infection were evaluated in an observational study from India of 60 children with nephrotic syndrome who were not receiving glucocorticoid therapy [<a href="#rid6">6</a>]. There were 57 episodes of infection, which included:</p><p class="bulletIndent1"><span class="glyph">●</span>Upper respiratory infection – 16 episodes</p><p class="bulletIndent1"><span class="glyph">●</span>Urinary tract infection – 13 episodes</p><p class="bulletIndent1"><span class="glyph">●</span>Peritonitis – 9 episodes</p><p class="bulletIndent1"><span class="glyph">●</span>Pneumonia – 8 episodes</p><p class="bulletIndent1"><span class="glyph">●</span>Severe acute gastroenteritis – 6 episodes</p><p class="bulletIndent1"><span class="glyph">●</span>Empyema – 3 episodes</p><p></p><p class="headingAnchor" id="H3"><span class="h2">Bacterial infection</span><span class="headingEndMark"> — </span>Children with nephrotic syndrome are at increased risk of developing serious bacterial infection, especially with encapsulated bacteria. This may be due in part to the loss of opsonizing factors, which may specifically increase susceptibility to encapsulated bacterial infection [<a href="#rid3">3,5</a>]. In addition, ascites and pleural effusions provide a natural culture media for bacterial growth. Thus, as noted in the above study, pneumonia, empyema, and peritonitis are infections seen in children with nephrotic syndrome [<a href="#rid6">6</a>].</p><p>In a retrospective review, 24 episodes of peritonitis occurred in 351 children with nephrotic syndrome over a 10-year period from 1970 to 1980 [<a href="#rid7">7</a>]. <em>Streptococcus pneumoniae was</em> the most common infectious agent, seen in 12 patients, followed by <em>Escherichia coli </em>in six, and negative cultures in four. Peritoneal signs of irritation were present in all patients, including in 16 who were receiving corticosteroid therapy.</p><p>In a retrospective study, eight episodes of peritonitis in seven patients over a five-year period were reported in 268 patients with nephrotic syndrome that was initially diagnosed as steroid sensitive [<a href="#rid8">8</a>]. In three cases the causative microorganism was identified as <em>S. pneumoniae</em>, <em>Streptococcus hemolyticus</em>, and <em>alpha-hemolytic Streptococcus</em>.</p><p>Sepsis, meningitis, and cellulitis are other serious infections that can occur in children with nephrotic syndrome [<a href="#rid9">9,10</a>]. Although not as serious, urinary tract infections are common [<a href="#rid6">6,11</a>].</p><p>Prior to 1940, the mortality rate in children with nephrotic syndrome was 40 percent, primarily due to infection [<a href="#rid12">12</a>]. Although the mortality rate has been significantly reduced with the introduction of corticosteroid treatment and antibiotics [<a href="#rid13">13,14</a>], infection still remains a cause of death in children with nephrotic syndrome. This was illustrated in an International Study of Kidney Disease in Children report of 10 deaths in a group of 389 children with minimal change disease (MCD) who were seen between 1967 and 1976 and were followed for 5 to 15 years [<a href="#rid15">15</a>]. Six of the deaths were due to infection, five were from sepsis (peritonitis as the primary site of infection in two), and one was due to peritonitis with pancreatitis. <em>S. pneumoniae </em>was isolated in two cases and <em>E. coli</em> in two other cases.</p><p>Because children with nephrotic syndrome are at increased risk for serious complications and potentially death from pneumococcal infection, they should receive 23-valent polysaccharide (<a class="drug drug_pediatric" data-topicid="12948" href="/d/drug information/12948.html" rel="external">PPSV23</a>) pneumococcal vaccine if not previously immunized. Pneumococcal vaccine is effective even in children receiving high doses of steroids and it is not associated with an increased risk of relapse [<a href="#rid16">16,17</a>]. (See  <a class="medical medical_review" href="/d/html/6053.html" rel="external">"Pneumococcal vaccination in children", section on 'Immunization of high-risk children and adolescents'</a>.)</p><p class="headingAnchor" id="H4"><span class="h2">Viral infections</span><span class="headingEndMark"> — </span>Viral infections, particularly varicella, may be observed in children with nephrotic syndrome, especially in those receiving immunosuppressive therapy. Varicella can cause significant morbidity and mortality in such patients [<a href="#rid18">18-20</a>]. Treatment including vaccination is discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/8336.html" rel="external">"Treatment of varicella (chickenpox) infection", section on 'Immunocompromised hosts'</a>.)</p><p>Idiopathic nephrotic syndrome is not clear risk factor for severe COVID-19 [<a href="#rid21">21</a>]. Although relapse of nephrotic syndrome may occur as a complication of SARS-CoV-2 infection, it can be effectively managed. (See  <a class="medical medical_review" href="/d/html/6130.html" rel="external">"Treatment of idiopathic nephrotic syndrome in children", section on 'Initial or infrequent relapse'</a>.)</p><p>Although live attenuated viral vaccines have been discouraged for use in children receiving immunosuppressive therapy, a prospective study reported that administration of live attenuated vaccines was immunogenic and safe in children with nephrotic syndrome receiving immunosuppressive therapy [<a href="#rid22">22</a>]. However, the children in this study, who were in remission, had reasonable cellular and humoral immunologic function as inclusion criteria for this study included CD4+ cell count &gt;500/mm3, normal lymphocyte blast transformation by phytohemagglutinin, and serum IgG levels &gt;300 mg/dL. Additional studies are needed to confirm the safety, response rate and identify factors that may impact on immunogenicity prior to routine administration of life attenuated viral vaccines in children with nephrotic syndrome who are receiving immunosuppressive therapy. </p><p class="headingAnchor" id="H5"><span class="h1">THROMBOEMBOLISM</span><span class="headingEndMark"> — </span>Several factors contribute to an increased risk of thromboembolic complications in children with nephrotic syndrome:</p><p class="bulletIndent1"><span class="glyph">●</span>Hypovolemia with hemoconcentration</p><p class="bulletIndent1"><span class="glyph">●</span>Immobility, especially in patients with anasarca</p><p class="bulletIndent1"><span class="glyph">●</span>Infection [<a href="#rid23">23</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>The presence of central venous catheter</p><p class="bulletIndent1"><span class="glyph">●</span>A possible underlying genetic thrombophilic tendency [<a href="#rid24">24</a>]</p><p></p><p>In addition to these abnormalities, the nephrotic syndrome is associated with a hypercoagulable state due to thrombocytosis, and hemostatic abnormalities including decreased levels of antithrombin III, free protein S, and plasminogen (due to urinary losses), increased levels of procoagulant proteins (fibrinogen, and factors V and VIII), and increased platelet activation. (See  <a class="medical medical_review" href="/d/html/3043.html" rel="external">"Hypercoagulability in nephrotic syndrome", section on 'Pathogenesis'</a>.)</p><p>The reported incidence of thromboembolic complications in nephrotic children is between 2 and 3 percent [<a href="#rid25">25,26</a>]. In a retrospective study of 326 children with nephrotic syndrome from any cause diagnosed between 1999 and 2006, 9 percent had one thromboembolic event (TEE), resulting in an overall incidence of 20.4 patients with TEEs per 1000 patient-years [<a href="#rid25">25</a>]. The median time to TEE was approximately 71 days after diagnosis of nephrotic syndrome. Deep venous thrombosis was the most common TEE and was associated with the use of a central venous catheter. Multivariate analysis demonstrated that the risk of TEE was greater in children older than 12 years of age, and increased with increasing urinary protein excretion.</p><p>However, the true incidence of TEE may be higher, as many TEEs are asymptomatic. This was illustrated in a case series of 16 children with steroid-dependent minimal change disease [<a href="#rid27">27</a>]. Evaluation by ventilation-perfusion scans showed defects consistent with pulmonary embolism in 7 patients, residual changes in 10, and normal findings in only 9. In another study using dual energy computed tomography (CT) pulmonary angiography, 28 percent of children with nephrotic syndrome without respiratory symptoms had subclinical pulmonary embolism [<a href="#rid28">28</a>].</p><p>Both arterial and venous thromboses have been reported in children with nephrotic syndrome, although venous thrombosis complication accounted for most of the cases. [<a href="#rid25">25</a>]. The most common sites include the cerebral vein, pulmonary artery, renal vein, deep leg veins, inferior vena cava, and femoral/iliac artery [<a href="#rid29">29-32</a>]. Other reported sites include the cerebral and meningeal arteries, and mesenteric and hepatic veins [<a href="#rid29">29,33,34</a>].</p><p>Thromboembolic complications in children with nephrotic syndrome may be associated with significant morbidity, including cerebral venous thrombosis, pulmonary embolism, and renal vein thrombosis.</p><p class="bulletIndent1"><span class="glyph">●</span>Pulmonary embolism − As mentioned above, many pulmonary emboli are silent in children with nephrotic syndrome [<a href="#rid27">27</a>]. However, there are several case reports of significant morbidity from pulmonary embolism [<a href="#rid35">35-37</a>]. Pulmonary embolism should be suspected in patients with pulmonary or cardiovascular symptoms and can be confirmed by angiography or radioisotope scanning [<a href="#rid38">38</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Renal vein thrombosis − Infants with congenital nephrotic syndrome are at increased risk for renal vein thrombosis. Otherwise, renal vein thrombosis is rare in children with nephrotic syndrome, especially in comparison with adults. However, some children develop acute complete venous occlusion, which is characterized clinically by the sudden onset of macroscopic hematuria, flank pain and/or tenderness, and, in children with bilateral disease, acute renal failure. In such cases, Doppler ultrasonography shows an increase in kidney size and the absence of blood flow in the renal vein. (See  <a class="medical medical_review" href="/d/html/3043.html" rel="external">"Hypercoagulability in nephrotic syndrome", section on 'Pathogenesis'</a>.)</p><p></p><p>Prophylactic anticoagulation is not recommended unless the patient has had a TEE or has a high risk of thrombosis with albumin concentration of less than 2 g/dL (20 g/L), a fibrinogen level of more than 6 g/L, or an antithrombin III level less than 70 percent of normal. (See  <a class="medical medical_review" href="/d/html/6113.html" rel="external">"Symptomatic management of nephrotic syndrome in children", section on 'Hypercoagulability'</a>.)</p><p class="headingAnchor" id="H6"><span class="h1">RENAL INSUFFICIENCY</span><span class="headingEndMark"> — </span>At presentation, children with nephrotic syndrome can have reduced glomerular filtration rate (GFR) because of one or more of the following mechanisms [<a href="#rid39">39</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Hypovolemia − Children with nephrotic syndrome, especially those with minimal change disease, can have a transient decrease in GFR due to hypovolemia that returns to normal after repletion of their vascular volume [<a href="#rid40">40-42</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Acute kidney injury (AKI) in children, although uncommon, may occur as a complication of infection, acute tubular necrosis (secondary to significant hypovolemia), allergic interstitial nephritis (due to antibiotics or nonsteroidal antiinflammatory drugs), drug toxicity, such as calcineurin-inhibitors (<a class="drug drug_pediatric" data-topicid="13193" href="/d/drug information/13193.html" rel="external">cyclosporine</a> or <a class="drug drug_pediatric" data-topicid="12822" href="/d/drug information/12822.html" rel="external">tacrolimus</a>, which are often used in children with steroid-dependent nephrotic syndrome) or angiotensin-converting enzyme (ACE) inhibitors [<a href="#rid39">39,41,43,44</a>]. AKI occurs more frequently in patients who are hospitalized. In a report from the Midwest Pediatric Nephrology Consortium, almost 60 percent of children hospitalized developed AKI [<a href="#rid43">43</a>]. Associated factors included steroid-resistant nephrotic syndrome, infection, and exposure to nephrotoxic medication.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Underlying glomerular pathology − In children with nephrotic syndrome, primary renal disease (eg, primary membranoproliferative glomerulonephritis [<a href="#rid40">40</a>]) or secondary renal disease (eg, postinfectious glomerulonephritis or lupus nephritis) can present with renal insufficiency due to glomerular injury. (See  <a class="medical medical_review" href="/d/html/6118.html" rel="external">"Poststreptococcal glomerulonephritis"</a> and  <a class="medical medical_review" href="/d/html/3056.html" rel="external">"Lupus nephritis: Diagnosis and classification"</a> and  <a class="medical medical_review" href="/d/html/3100.html" rel="external">"Focal segmental glomerulosclerosis: Treatment and prognosis", section on 'Prognosis'</a>.)</p><p></p><p>Minimal change disease (MCD), which is the most common form of nephrotic syndrome in children, particularly in those younger than age six years, may present with mild elevations in serum creatinine, but substantial declines in GFR are uncommon [<a href="#rid39">39</a>]. In one study, a decrease in GFR appeared to correlate with an increased degree of fusion of the foot processes [<a href="#rid45">45</a>]. (See  <a class="medical medical_review" href="/d/html/6101.html" rel="external">"Clinical manifestations, diagnosis, and evaluation of nephrotic syndrome in children"</a> and  <a class="medical medical_review" href="/d/html/3047.html" rel="external">"Acute kidney injury (AKI) in minimal change disease and other forms of nephrotic syndrome"</a>.)</p><p>Progression to chronic or end-stage renal failure can occur in some patients, especially those who with steroid-resistant nephrotic syndrome. (See  <a class="medical medical_review" href="/d/html/6130.html" rel="external">"Treatment of idiopathic nephrotic syndrome in children", section on 'Outcome based on response'</a>.)</p><p class="headingAnchor" id="H7"><span class="h1">ANASARCA</span><span class="headingEndMark"> — </span>Anasarca (generalized and massive edema) can be associated with the following complications:</p><p class="bulletIndent1"><span class="glyph">●</span>Inability to walk because of severe scrotal or vulvar edema</p><p class="bulletIndent1"><span class="glyph">●</span>Respiratory distress from large pleural effusions, and/or massive ascites, which can impair diaphragmatic movement</p><p class="bulletIndent1"><span class="glyph">●</span>Tissue breakdown and cellulitis</p><p></p><p>Management of anasarca is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/6113.html" rel="external">"Symptomatic management of nephrotic syndrome in children", section on 'Edema'</a>.)</p><p class="headingAnchor" id="H8"><span class="h1">HYPOVOLEMIA</span><span class="headingEndMark"> — </span>Despite the marked increase in extracellular fluid volume, some children with nephrotic syndrome, primarily those with minimal change disease (MCD), present with or develop signs of a decrease in effective circulating volume such as tachycardia, peripheral vasoconstriction, oliguria, decreased glomerular filtration rate, and elevation of plasma renin aldosterone [<a href="#rid42">42</a>]. Hypovolemia typically occurs early at onset of nephrosis or during a relapse. In such children, a further insult such as diuretic therapy, sepsis, or diarrhea can lead to hypotension and, rarely, shock [<a href="#rid46">46</a>]. </p><p class="headingAnchor" id="H9"><span class="h1">GROWTH</span><span class="headingEndMark"> — </span>Growth can be adversely affected in patients with persistent nephrotic syndrome or as a complication of long-term steroid therapy in patients with steroid-dependent nephrotic syndrome. (See  <a class="medical medical_review" href="/d/html/6130.html" rel="external">"Treatment of idiopathic nephrotic syndrome in children", section on 'Alternative treatments for patients with steroid toxicity'</a> and  <a class="medical medical_review" href="/d/html/5832.html" rel="external">"Causes of short stature", section on 'Glucocorticoid therapy'</a>.)</p><p class="headingAnchor" id="H1249019822"><span class="h1">OTHER POTENTIAL COMPLICATIONS</span><span class="headingEndMark"> — </span>Other potential complications that may occur in children with nephrotic syndrome include:</p><p class="bulletIndent1"><span class="glyph">●</span>Dyslipidemia – Hyperlipidemia in nephrotic syndrome is common and is characterized by elevated total cholesterol, LDL cholesterol, and triglyceride levels with normal or low HDL cholesterol levels. Dyslipidemia contributes to an increased risk of cardiovascular and thrombotic complications [<a href="#rid47">47,48</a>]. This is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/3114.html" rel="external">"Lipid abnormalities in nephrotic syndrome", section on 'Common lipid abnormalities'</a> and  <a class="medical medical_review" href="/d/html/3114.html" rel="external">"Lipid abnormalities in nephrotic syndrome", section on 'Clinical implications'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Anemia – Patients with persistent nephrotic syndrome may develop anemia due to urinary losses of iron, transferrin, erythropoietin, transcobalamin, and/or metals such as copper [<a href="#rid49">49</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Abnormal endocrine tests and possible function – Patients with nephrotic syndrome may have low total T4 and T3 levels but normal serum free T4 and T3 and thyrotropin (TSH) concentrations, and as a result are usually clinically euthyroid. In addition, serum calcidiol (25-hydroxyvitamin D) and calcitriol concentrations may be reduced [<a href="#rid50">50</a>], but the physiologic serum free calcitriol concentration is normal [<a href="#rid51">51</a>]. (See  <a class="medical medical_review" href="/d/html/3104.html" rel="external">"Endocrine dysfunction in the nephrotic syndrome", section on 'Thyroid function'</a> and  <a class="medical medical_review" href="/d/html/3104.html" rel="external">"Endocrine dysfunction in the nephrotic syndrome", section on 'Vitamin D and calcium metabolism'</a>.)</p><p></p><p class="headingAnchor" id="H1151101225"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/110405.html" rel="external">"Society guideline links: Nephrotic syndrome in children"</a>.)</p><p class="headingAnchor" id="H10"><span class="h1">SUMMARY</span><span class="headingEndMark"> — </span>Complications result from abnormalities directly related to the nephrotic syndrome. They include the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infection</strong> − Children with nephrotic syndrome have increased susceptibility to encapsulated bacterial infection, particularly peritonitis because of defects in humoral immunity. Although antibiotics have reduced the mortality rate of nephrotic syndrome due to infection, infection still remains a cause of death in children with nephrotic syndrome. (See <a class="local">'Infection'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anasarca</strong> − Anasarca (generalized and massive edema) can cause respiratory distress (eg, large pleural effusions and/or massive ascites) and skin breakdown with an increased risk of cellulitis, and increases the risk of bacterial peritonitis. (See <a class="local">'Anasarca'</a> above and <a class="local">'Bacterial infection'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Thrombosis</strong> − Children with nephrotic syndrome are at increased risk for thrombosis due primarily to hypercoagulability from thrombocytosis and hemostatic abnormalities. Arterial and venous thromboses occur and involve a variety of different sites. (See <a class="local">'Thromboembolism'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Renal insufficiency </strong>− Children with nephrotic syndrome can have transient impaired renal function at presentation because of hypovolemia, or persistent renal insufficiency because of glomerular injury from the underlying disease process. (See <a class="local">'Renal insufficiency'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypovolemia</strong> − Significant hypovolemia in children with nephrotic syndrome can be associated with hypotension, abdominal pain, and cold poorly perfused extremities. In rare and severe cases, shock can occur. (See <a class="local">'Hypovolemia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Growth</strong> − Poor growth can be seen in patients with persistent nephrotic syndrome or in patients with steroid-dependent nephrotic syndrome who are treated with long-term steroid therapy. (See <a class="local">'Growth'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Giangiacomo J, Cleary TG, Cole BR, et al. Serum immunoglobulins in the nephrotic syndrome. A possible cause of minimal-change nephrotic syndrome. N Engl J Med 1975; 293:8.</a></li><li><a class="nounderline abstract_t">Spika JS, Halsey NA, Fish AJ, et al. Serum antibody response to pneumococcal vaccine in children with nephrotic syndrome. Pediatrics 1982; 69:219.</a></li><li><a class="nounderline abstract_t">McLean RH, Forsgren A, Björkstén B, et al. Decreased serum factor B concentration associated with decreased opsonization of Escherichia coli in the idiopathic nephrotic syndrome. Pediatr Res 1977; 11:910.</a></li><li><a class="nounderline abstract_t">Anderson DC, York TL, Rose G, Smith CW. Assessment of serum factor B, serum opsonins, granulocyte chemotaxis, and infection in nephrotic syndrome of children. J Infect Dis 1979; 140:1.</a></li><li><a class="nounderline abstract_t">Ballow M, Kennedy TL 3rd, Gaudio KM, et al. Serum hemolytic factor D values in children with steroid-responsive idiopathic nephrotic syndrome. J Pediatr 1982; 100:192.</a></li><li><a class="nounderline abstract_t">Alwadhi RK, Mathew JL, Rath B. Clinical profile of children with nephrotic syndrome not on glucorticoid therapy, but presenting with infection. J Paediatr Child Health 2004; 40:28.</a></li><li><a class="nounderline abstract_t">Krensky AM, Ingelfinger JR, Grupe WE. Peritonitis in childhood nephrotic syndrome: 1970-1980. Am J Dis Child 1982; 136:732.</a></li><li><a class="nounderline abstract_t">Uncu N, Bülbül M, Yildiz N, et al. Primary peritonitis in children with nephrotic syndrome: results of a 5-year multicenter study. Eur J Pediatr 2010; 169:73.</a></li><li><a class="nounderline abstract_t">Wilfert CM, Katz SL. Etiology of bacterial sepsis in nephrotic children 1963-1967. Pediatrics 1968; 42:840.</a></li><li><a class="nounderline abstract_t">Sleiman JN, D'Angelo A, Hammerschlag MR. Spontaneous Escherichia coli cellulitis in a child with nephrotic syndrome. Pediatr Infect Dis J 2007; 26:266.</a></li><li><a class="nounderline abstract_t">Gulati S, Kher V, Arora P, et al. Urinary tract infection in nephrotic syndrome. Pediatr Infect Dis J 1996; 15:237.</a></li><li><a class="nounderline abstract_t">Barness LA, Moll GH, Janeway CA. Nephrotic Syndrome. I. Natural History of the Disease. Pediatrics 1950; 5:486.</a></li><li><a class="nounderline abstract_t">LAWSON D, MONCRIEFF A, PAYNE WW. Forty years of nephrosis in childhood. Arch Dis Child 1960; 35:115.</a></li><li><a class="nounderline abstract_t">ARNEIL GC. 164 children with nephrosis. Lancet 1961; 2:1103.</a></li><li><a class="nounderline abstract_t">Minimal change nephrotic syndrome in children: deaths during the first 5 to 15 years' observation. Report of the International Study of Kidney Disease in Children. Pediatrics 1984; 73:497.</a></li><li><a class="nounderline abstract_t">Ulinski T, Leroy S, Dubrel M, et al. High serological response to pneumococcal vaccine in nephrotic children at disease onset on high-dose prednisone. Pediatr Nephrol 2008; 23:1107.</a></li><li><a class="nounderline abstract_t">Goonewardene ST, Tang C, Tan LT, et al. Safety and Efficacy of Pneumococcal Vaccination in Pediatric Nephrotic Syndrome. Front Pediatr 2019; 7:339.</a></li><li><a class="nounderline abstract_t">Close GC, Houston IB. Fatal haemorrhagic chickenpox in a child on long-term steroids. Lancet 1981; 2:480.</a></li><li><a class="nounderline abstract_t">Scheinman JI, Stamler FW. Cyclophosphamide and fatal varicella. J Pediatr 1969; 74:117.</a></li><li><a class="nounderline abstract_t">Resnick J, Schanberger JE. Varicella reactivation in nephrotic syndrome treated with cyclophosphamide and adrenal corticosteroids. J Pediatr 1973; 83:451.</a></li><li><a class="nounderline abstract_t">Morello W, Vianello FA, Proverbio E, et al. COVID-19 and idiopathic nephrotic syndrome in children: systematic review of the literature and recommendations from a highly affected area. Pediatr Nephrol 2022; 37:757.</a></li><li><a class="nounderline abstract_t">Kamei K, Miyairi I, Ishikura K, et al. Prospective Study of Live Attenuated Vaccines for Patients with Nephrotic Syndrome Receiving Immunosuppressive Agents. J Pediatr 2018; 196:217.</a></li><li><a class="nounderline abstract_t">Carpenter SL, Goldman J, Sherman AK, et al. Association of infections and venous thromboembolism in hospitalized children with nephrotic syndrome. Pediatr Nephrol 2019; 34:261.</a></li><li><a class="nounderline abstract_t">Ismail G, Obrișcă B, Jurubiță R, et al. Inherited Risk Factors of Thromboembolic Events in Patients with Primary Nephrotic Syndrome. Medicina (Kaunas) 2020; 56.</a></li><li><a class="nounderline abstract_t">Kerlin BA, Blatt NB, Fuh B, et al. Epidemiology and risk factors for thromboembolic complications of childhood nephrotic syndrome: a Midwest Pediatric Nephrology Consortium (MWPNC) study. J Pediatr 2009; 155:105.</a></li><li><a class="nounderline abstract_t">Lilova MI, Velkovski IG, Topalov IB. Thromboembolic complications in children with nephrotic syndrome in Bulgaria (1974-1996). Pediatr Nephrol 2000; 15:74.</a></li><li><a class="nounderline abstract_t">Hoyer PF, Gonda S, Barthels M, et al. Thromboembolic complications in children with nephrotic syndrome. Risk and incidence. Acta Paediatr Scand 1986; 75:804.</a></li><li><a class="nounderline abstract_t">Zhang LJ, Zhang Z, Li SJ, et al. Pulmonary embolism and renal vein thrombosis in patients with nephrotic syndrome: prospective evaluation of prevalence and risk factors with CT. Radiology 2014; 273:897.</a></li><li><a class="nounderline abstract_t">Cameron JS. Coagulation and thromboembolic complications in the nephrotic syndrome. Adv Nephrol Necker Hosp 1984; 13:75.</a></li><li><a class="nounderline abstract_t">Sullivan MJ 3rd, Hough DR, Agodoa LC. Peripheral arterial thrombosis due to the nephrotic syndrome: the clinical spectrum. South Med J 1983; 76:1011.</a></li><li><a class="nounderline abstract_t">Suri D, Ahluwalia J, Saxena AK, et al. Thromboembolic complications in childhood nephrotic syndrome: a clinical profile. Clin Exp Nephrol 2014; 18:803.</a></li><li><a class="nounderline abstract_t">Egli F, Elmiger P, Stalder G. [Thrombosis as a complication of nephrotic syndrome]. Helv Paediatr Acta 1973; 30:Suppl:20.</a></li><li><a class="nounderline abstract_t">Appenzeller S, Zeller CB, Annichino-Bizzachi JM, et al. Cerebral venous thrombosis: influence of risk factors and imaging findings on prognosis. Clin Neurol Neurosurg 2005; 107:371.</a></li><li><a class="nounderline abstract_t">Igarashi M, Roy S 3rd, Stapleton FB. Cerebrovascular complications in children with nephrotic syndrome. Pediatr Neurol 1988; 4:362.</a></li><li><a class="nounderline abstract_t">Deshpande PV, Griffiths M. Pulmonary thrombosis in steroid-sensitive nephrotic syndrome. Pediatr Nephrol 2005; 20:665.</a></li><li><a class="nounderline abstract_t">Apostol EL, Kher KK. Cavitating pulmonary infarction in nephrotic syndrome. Pediatr Nephrol 1994; 8:347.</a></li><li><a class="nounderline abstract_t">Jones CL, Hébert D. Pulmonary thrombo-embolism in the nephrotic syndrome. Pediatr Nephrol 1991; 5:56.</a></li><li><a class="nounderline abstract_t">Rai Mittal B, Singh S, Bhattacharya A, et al. Lung scintigraphy in the diagnosis and follow-up of pulmonary thromboembolism in children with nephrotic syndrome. Clin Imaging 2005; 29:313.</a></li><li><a class="nounderline abstract_t">Meyrier A, Niaudet P. Acute kidney injury complicating nephrotic syndrome of minimal change disease. Kidney Int 2018; 94:861.</a></li><li><a class="nounderline abstract_t">Nephrotic syndrome in children: prediction of histopathology from clinical and laboratory characteristics at time of diagnosis. A report of the International Study of Kidney Disease in Children. Kidney Int 1978; 13:159.</a></li><li><a class="nounderline abstract_t">Agarwal N, Phadke KD, Garg I, Alexander P. Acute renal failure in children with idiopathic nephrotic syndrome. Pediatr Nephrol 2003; 18:1289.</a></li><li><a class="nounderline abstract_t">Vande Walle JG, Donckerwolcke RA, van Isselt JW, et al. Volume regulation in children with early relapse of minimal-change nephrosis with or without hypovolaemic symptoms. Lancet 1995; 346:148.</a></li><li><a class="nounderline abstract_t">Rheault MN, Zhang L, Selewski DT, et al. AKI in Children Hospitalized with Nephrotic Syndrome. Clin J Am Soc Nephrol 2015; 10:2110.</a></li><li><a class="nounderline abstract_t">Kim MY, Cho MH, Kim JH, et al. Acute kidney injury in childhood-onset nephrotic syndrome: Incidence and risk factors in hospitalized patients. Kidney Res Clin Pract 2018; 37:347.</a></li><li><a class="nounderline abstract_t">Bohman SO, Jaremko G, Bohlin AB, Berg U. Foot process fusion and glomerular filtration rate in minimal change nephrotic syndrome. Kidney Int 1984; 25:696.</a></li><li><a class="nounderline abstract_t">Yamauchi H, Hopper J Jr. Hypovolemic shock and hypotension as a complication in the nephrotic syndrome. Report of ten cases. Ann Intern Med 1964; 60:242.</a></li><li><a class="nounderline abstract_t">Hari P, Khandelwal P, Smoyer WE. Dyslipidemia and cardiovascular health in childhood nephrotic syndrome. Pediatr Nephrol 2020; 35:1601.</a></li><li><a class="nounderline abstract_t">Agrawal S, Zaritsky JJ, Fornoni A, Smoyer WE. Dyslipidaemia in nephrotic syndrome: mechanisms and treatment. Nat Rev Nephrol 2018; 14:57.</a></li><li><a class="nounderline abstract_t">Iorember F, Aviles D. Anemia in nephrotic syndrome: approach to evaluation and treatment. Pediatr Nephrol 2017; 32:1323.</a></li><li><a class="nounderline abstract_t">Selewski DT, Chen A, Shatat IF, et al. Vitamin D in incident nephrotic syndrome: a Midwest Pediatric Nephrology Consortium study. Pediatr Nephrol 2016; 31:465.</a></li><li><a class="nounderline abstract_t">Banerjee S, Basu S, Akhtar S, et al. Free vitamin D levels in steroid-sensitive nephrotic syndrome and healthy controls. Pediatr Nephrol 2020; 35:447.</a></li></ol></div><div id="topicVersionRevision">Topic 6102 Version 24.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1079322" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Serum immunoglobulins in the nephrotic syndrome. A possible cause of minimal-change nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7058096" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Serum antibody response to pneumococcal vaccine in children with nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/407543" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Decreased serum factor B concentration associated with decreased opsonization of Escherichia coli in the idiopathic nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/379244" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Assessment of serum factor B, serum opsonins, granulocyte chemotaxis, and infection in nephrotic syndrome of children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6915968" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Serum hemolytic factor D values in children with steroid-responsive idiopathic nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14718000" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Clinical profile of children with nephrotic syndrome not on glucorticoid therapy, but presenting with infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7048898" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Peritonitis in childhood nephrotic syndrome: 1970-1980.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19430812" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Primary peritonitis in children with nephrotic syndrome: results of a 5-year multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5685368" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Etiology of bacterial sepsis in nephrotic children 1963-1967.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17484229" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Spontaneous Escherichia coli cellulitis in a child with nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8852912" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Urinary tract infection in nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Nephrotic Syndrome. I. Natural History of the Disease</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14414748" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Forty years of nephrosis in childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13862397" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : 164 children with nephrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6709428" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Minimal change nephrotic syndrome in children: deaths during the first 5 to 15 years' observation. Report of the International Study of Kidney Disease in Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18324419" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : High serological response to pneumococcal vaccine in nephrotic children at disease onset on high-dose prednisone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31456997" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Safety and Efficacy of Pneumococcal Vaccination in Pediatric Nephrotic Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6115244" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Fatal haemorrhagic chickenpox in a child on long-term steroids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5782815" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Cyclophosphamide and fatal varicella.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4353458" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Varicella reactivation in nephrotic syndrome treated with cyclophosphamide and adrenal corticosteroids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34687377" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : COVID-19 and idiopathic nephrotic syndrome in children: systematic review of the literature and recommendations from a highly affected area.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29499990" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Prospective Study of Live Attenuated Vaccines for Patients with Nephrotic Syndrome Receiving Immunosuppressive Agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30194664" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Association of infections and venous thromboembolism in hospitalized children with nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32438633" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Inherited Risk Factors of Thromboembolic Events in Patients with Primary Nephrotic Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19394032" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Epidemiology and risk factors for thromboembolic complications of childhood nephrotic syndrome: a Midwest Pediatric Nephrology Consortium (MWPNC) study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11095017" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Thromboembolic complications in children with nephrotic syndrome in Bulgaria (1974-1996).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2436435" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Thromboembolic complications in children with nephrotic syndrome. Risk and incidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25072187" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Pulmonary embolism and renal vein thrombosis in patients with nephrotic syndrome: prospective evaluation of prevalence and risk factors with CT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6433673" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Coagulation and thromboembolic complications in the nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6410516" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Peripheral arterial thrombosis due to the nephrotic syndrome: the clinical spectrum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24346593" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Thromboembolic complications in childhood nephrotic syndrome: a clinical profile.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4711235" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : [Thrombosis as a complication of nephrotic syndrome].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16023530" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Cerebral venous thrombosis: influence of risk factors and imaging findings on prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3072964" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Cerebrovascular complications in children with nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15778847" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Pulmonary thrombosis in steroid-sensitive nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7917865" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Cavitating pulmonary infarction in nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2025540" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Pulmonary thrombo-embolism in the nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16153536" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Lung scintigraphy in the diagnosis and follow-up of pulmonary thromboembolism in children with nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29980292" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Acute kidney injury complicating nephrotic syndrome of minimal change disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/713276" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Nephrotic syndrome in children: prediction of histopathology from clinical and laboratory characteristics at time of diagnosis. A report of the International Study of Kidney Disease in Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14579139" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Acute renal failure in children with idiopathic nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7603230" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Volume regulation in children with early relapse of minimal-change nephrosis with or without hypovolaemic symptoms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26450933" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : AKI in Children Hospitalized with Nephrotic Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30619690" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Acute kidney injury in childhood-onset nephrotic syndrome: Incidence and risk factors in hospitalized patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6482174" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Foot process fusion and glomerular filtration rate in minimal change nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14114444" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Hypovolemic shock and hypotension as a complication in the nephrotic syndrome. Report of ten cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31302760" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Dyslipidemia and cardiovascular health in childhood nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29176657" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Dyslipidaemia in nephrotic syndrome: mechanisms and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27999949" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Anemia in nephrotic syndrome: approach to evaluation and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26498119" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Vitamin D in incident nephrotic syndrome: a Midwest Pediatric Nephrology Consortium study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31845055" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Free vitamin D levels in steroid-sensitive nephrotic syndrome and healthy controls.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
